期刊文献+

超滤渗滤过程中不溶性颗粒产生的控制研究

Particle Formation Control During Ultrafiltration/Diafiltration
下载PDF
导出
摘要 目的:目标单抗在超滤渗滤过程中易产生不溶性颗粒,堵塞膜包,使膜包通量降低,换液无法顺利进行,因此要控制超滤渗滤步骤中不溶性颗粒的产生,完成蛋白质浓缩换液过程。方法:通过比较不同缓冲液体系、不同添加剂、是否进行搅拌找出不溶性颗粒产生的原因和控制方法。结果:不溶性颗粒的产生与缓冲液体系无关,而与搅拌有关;在超滤渗滤进行时,必须使用搅拌来保证样品的均一性;加入吐温可有效控制不溶性颗粒的产生。结论:大部分的单抗处方中,吐温均会作为一种表面活性剂加入,本研究最终采用提前加入吐温方式,使超滤渗滤正常运行。 Objective:The target monoclonal antibody(mAb)in this study was prone to produce particles during ultrafiltration/diafiltration(UF/DF),and then block the UF/DF membrane,decrease the UF/DF permeate flux.TheUF/DF can’t complete successfully.The objective of this study was to control the paticle formation during UF/DF,making UF/DF complete smoothly.Mehtod:The causes and control methods of particles were found by comparing different buffer systems,different additives and agitation.Results:The formation of insoluble particles has no related with buffer system but with agitation.But agitation was necessary in UF/DF process.Adding tween in UF/DF sample can control particle formation.Conclusion:In most monoclonal antibody prescriptions,tween is added as a surfactant.In this study,tween is added in advance to ensure the normal operation of ultrafiltration.
作者 罗映 贺芸芬 刘建平 Luo Ying;He Yun-fen;Liu Jian-ping(Shanghai OPM BiosciencesCo.,Ltd.,Shanghai201318;School of life sciences,ShanghaiFudan University,Shanghai200433)
出处 《生物化工》 2020年第3期32-35,共4页 Biological Chemical Engineering
关键词 单抗 纯化工艺 超滤渗滤 不溶性颗粒产生 Monoclonal antibody Purification process Ultrafiltration/diafiltration Particle formation
  • 相关文献

参考文献1

二级参考文献22

  • 1Reichert JM. Antibodies to watch in 2016. MAbs, 2016, 8(2):197-204. 被引量:1
  • 2Singh N, Arunkumar A, Chollanqi S, et al. Clarification technologies for monoclonal antibody manufacturing processes: current state and future perspectives. Biotechnol Bioeng, 2016, 13(4):698-716. 被引量:1
  • 3Langer ES. Trends in capacity utilization for therapeutic monoclonal antibody production. MAbs, 2009, 1(2):151-156. 被引量:1
  • 4Girard V, Hilbold NJ, Ng CK, et al. Large-scale monoclonal antibody purification by continuous chromatography, from process design to scale-up. J Biotechnol, 2015, 213 ( 10):65-73. 被引量:1
  • 5Zydney AL. Continuous downstream processing for high value biological products: A Review. Biotechnol Bioeng, 2016, 113(3):465- 475. 被引量:1
  • 6Klutz S, Holtmann L, Lobedann M, et al. Cost evaluation of antibody production processes in different operation modes. Chem Eng Sci, 2016, 17(141):63-74. 被引量:1
  • 7Rathore AS, Aqarwal H, Sharma AK, et al. Continuous processing for production of biopharmaceuticals. Prep Biochem Biotechnol, 2015, 45(8):836-849. 被引量:1
  • 8Gagnon P. Technology trends in antibody purification. J Chromatogr A, 2012, 1221:57-70. 被引量:1
  • 9Baur D, Angarita M, Miiller-Spith T, et al. Optimal model-based design of the twin-column CaptureSMB process improves capacity utilization and productivity in protein A affinity capture. Biotecbnol J, 2016, 11(1):135-145. 被引量:1
  • 10Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. MAbs, 2015, 7(1):9-14. 被引量:1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部